Prolactin regulation of the prostate gland: A female player in a male game

Nature Reviews Urology

Volumn 8, Issue 11, 2011, Pages 597-607

  Goffin, Vincent ^a   Hoang, David T ^b   Bogorad, Roman L ^a   Nevalainen, Marja T ^b  

^a INSERM   (France)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AZD 1480; DOPAMINE RECEPTOR STIMULATING AGENT; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MONOCLONAL ANTIBODY; PROLACTIN; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; STAT5A PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; DIMERIZATION; DRUG TARGETING; HORMONAL REGULATION; HORMONE ACTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; GENE TARGETING; HUMANS; MALE; PROLACTIN; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION;

EID: 81055147508     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.143     Document Type: Review

References (128)

1. Riddle, O., Bates, R. W. & Dykshorn, S. W. The preparation, identification and assay of prolactin-a hormone of the anterior pituitary. Am. J. Physiol. 105, 191-216 (1933).
2. Kelly, P. A., Djiane, J., Postel-Vinay, M. C. & Edery, M. The prolactin/growth hormone receptor family. Endocr. Rev. 12, 235-251 (1991).
3. Bole-Feysot, C., Goffin, V., Edery, M., Binart, N. & Kelly, P. A. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 19, 225-268 (1998). (Pubitemid 29117815)
4. Ormandy, C. J. et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 11, 167-178 (1997). (Pubitemid 27081894)
5. Horseman, N. D. et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16, 6926-6935 (1997). (Pubitemid 27520793)
6. Liu, X. et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11, 179-186 (1997). (Pubitemid 27081895)
7. Ben-Jonathan, N., LaPensee, C. R. & LaPensee, E. W. What can we learn from rodents about prolactin in humans Endocr. Rev. 29, 1-41 (2008). (Pubitemid 351252745)
8. Ramot, Y. et al. Prolactin-a novel neuroendocrine regulator of human keratin expression in situ. FASEB J. 24, 1768-1779 (2010).
9. LaPensee, C. R. et al. The prolactin-deficient mouse has an unaltered metabolic phenotype. Endocrinology 147, 4638-4645 (2006). (Pubitemid 44402169)
10. Dorshkind, K. & Horseman, N. D. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr. Rev. 21, 292-312 (2000). (Pubitemid 32275590)
11. Flores, A., Segaloff, A. & Steelman, S. L. Prolactin as a factor in the ventral prostate assay for luteinizing hormone. Endocrinology 59, 233-240 (1956).
12. Costello, L. C. & Franklin, R. B. Effect of prolactin on the prostate. Prostate 24, 162-166 (1994). (Pubitemid 24109598)
13. Nevalainen, M. T. et al. Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Invest. 99, 618-627 (1997). (Pubitemid 27097662)
14. Newball, H. H. & Byar, D. P. Does reserpine increase prolactin and exacerbate cancer of prostate Case control study. Urology 2, 525-529 (1973).
15. Rouet, V. et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc. Natl Acad. Sci. USA 107, 15199-15204 (2010).
16. Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P. & Witte, O. N. Identification of a cell of origin for human prostate cancer. Science 329, 568-571 (2010).
17. Walvoord, D. J., Resnick, M. I. & Grayhack, J. T. Effect of testosterone, dihydrotestosterone, estradiol, and prolactin on the weight and citric acid content of the lateral lobe of the rat prostate. Invest. Urol. 14, 60-65 (1976).
18. Coert, A., Nievelstein, H., Kloosterboer, H. J., Loonen, P. & van deer Vies, J. Effects of hyperprolactinemia on the accessory sexual organs of the male rat. Prostate 6, 269-276 (1985). (Pubitemid 15111836)
19. Jones, R., Riding, P. R. & Parker, M. G. Effects of prolactin on testosterone-induced growth and protein synthesis in rat accessory sex glands. J. Endocrinol. 96, 407-416 (1983). (Pubitemid 13154169)
20. Holland, J. M. & Lee, C. Effects of pituitary grafts on testosterone stimulated growth of rat prostate. Biol. Reprod. 22, 351-355 (1980). (Pubitemid 10115424)
21. Thomas, J. A. & Manandhar, M. S. Effects of prolactin on the dorsolateral lobe of the rat prostate gland. Invest. Urol. 14, 398-399 (1977). (Pubitemid 8074139)
22. Schacht, M. J. et al. A local direct effect of pituitary graft on growth of the lateral prostate in rats. Prostate 20, 51-58 (1992).
23. Keenan, E. J., Klase, P. A. & Thomas, J. A. Effects of prolactin on DNA synthesis and growth of the accessory sex organs in male mice. Endocrinology 109, 170-175 (1981). (Pubitemid 11042469)
24. Prins, G. S. Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal, and lateral lobes of the rat prostate. Endocrinology 120, 1457-1464 (1987). (Pubitemid 17054000)
25. Adams, J. B. Control of secretion and the function of C19-delta 5-steroids of the human adrenal gland. Mol. Cell Endocrinol. 41, 1-17 (1985). (Pubitemid 15037816)
26. Nevalainen, M. T. et al. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 129, 612-622 (1991).
27. Ahonen, T. J. et al. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140, 5412-5421 (1999).
28. Ahonen, T. J., Harkonen, P. L., Rui, H. & Nevalainen, M. T. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143, 228-238 (2002). (Pubitemid 34056424)
29. Li, H. et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 64, 4774-4782 (2004). (Pubitemid 38924520)
30. Dagvadorj, A. et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 148, 3089-3101 (2007). (Pubitemid 46996970)
31. Reiter, E. et al. Growth hormone and prolactin stimulate androgen receptor, insulin-like growth factor-I (IGF-I) and IGF-I receptor levels in the prostate of immature rats. Mol. Cell Endocrinol. 88, 77-87 (1992).
32. Steger, R. W., Chandrashekar, V., Zhao, W., Bartke, A. & Horseman, N. D. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. Endocrinology 139, 3691-3695 (1998). (Pubitemid 28512246)
33. Robertson, F. G. et al. Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology 144, 3196-3205 (2003). (Pubitemid 36819922)
34. Nevalainen, M. T. et al. Epithelial defect in prostates of Stat5a-null mice. Lab. Invest. 80, 993-1006 (2000). (Pubitemid 30483218)
35. Abate-Shen, C. & Shen, M. M. Molecular genetics of prostate cancer. Genes Dev. 14, 2410-2434 (2000).
36. McNeal, J. E. The zonal anatomy of the prostate. Prostate 2, 35-49 (1981). (Pubitemid 11030893)
37. Wennbo, H., Kindblom, J., Isaksson, O. G. & Tornell, J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138, 4410-4415 (1997). (Pubitemid 27408488)
38. Kindblom, J. et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144, 2269-2278 (2003). (Pubitemid 36629877)
39. Kindblom, J., Dillner, K., Ling, C., Tornell, J. & Wennbo, H. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 53, 24-33 (2002). (Pubitemid 34966861)
40. Van Coppenolle, F. et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am. J. Physiol. Endocrinol. Metab. 280, E120-E129 (2001).
41. Syms, A. J., Harper, M. E. & Griffiths, K. The effect of prolactin on human BPH epithelial cell proliferation. Prostate 6, 145-153 (1985). (Pubitemid 15108340)
42. Leav, I. et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am. J. Pathol. 154, 863-870 (1999). (Pubitemid 29122605)
43. Rannikko, S. & Adlercreutz, H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 4, 223-229 (1983). (Pubitemid 13057787)
44. Colao, A. et al. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J. Clin. Endocrinol. Metab. 89, 2770-2775 (2004). (Pubitemid 38766364)
45. Nickel, J. C. Inflammation and benign prostatic hyperplasia. Urol. Clin. North Am. 35, 109-115 (2008). (Pubitemid 350166524)
46. Wang, L., Yang, J. R., Yang, L. Y. & Liu, Z. T. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med. Hypotheses 70, 1021-1023 (2008). (Pubitemid 351400693)
47. De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269 (2007). (Pubitemid 46486616)
48. Tangbanluekal, L. & Robinette, C. L. Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology 132, 2407-2416 (1993). (Pubitemid 23156888)
49. Gilleran, J. P. et al. The role of prolactin in the prostatic inflammatory response to neonatal estrogen. Endocrinology 144, 2046-2054 (2003). (Pubitemid 36543345)
50. McPherson, S. J. et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142, 2458-2467 (2001). (Pubitemid 32473102)
51. Yatkin, E., Bernoulli, J., Talvitie, E. M. & Santti, R. Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int. J. Androl. 32, 399-410 (2009).
52. Stattin, P. et al. Plasma prolactin and prostate cancer risk: A prospective study. Int. J. Cancer 92, 463-465 (2001). (Pubitemid 32249727)
53. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. & Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer Inst. 88, 1118-1126 (1996). (Pubitemid 26274606)
54. Eaton, N. E., Reeves, G. K., Appleby, P. N. & Key, T. J. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer 80, 930-934 (1999). (Pubitemid 29233911)
55. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126 (2000). (Pubitemid 32260350)
56. Janssen, T. et al. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 77, 144-149 (1996). (Pubitemid 26002750)
57. Xu, X., Kreye, E., Kuo, C. B. & Walker, A. M. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when du145 human prostate cancer cells were grown in nude mice. Cancer Res. 61, 6098-6104 (2001). (Pubitemid 32762545)
58. Peirce, S. K., Chen, W. Y. & Chen, W. Y. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J. Endocrinol. 171, R1-R4 (2001). (Pubitemid 32975934)
59. Ahonen, T. J. et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J. Biol. Chem. 278, 27287-27292 (2003). (Pubitemid 36876886)
60. Suwa, T., Nyska, A., Haseman, J. K., Mahler, J. F. & Maronpot, R. R. Spontaneous lesions in control B6C3F1 mice and recommended sectioning of male accessory sex organs. Toxicol. Pathol. 30, 228-234 (2002). (Pubitemid 34293047)
61. Lawson, D. A. et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl Acad. Sci. USA 107, 2610-2615.
62. Wang, X. et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500 (2009).
63. Rao, Y. P., Buckley, D. J. & Buckley, A. R. Rapid activation of mitogen-activated protein kinase and p21ras by prolactin and interleukin 2 in rat Nb2 node lymphoma cells. Cell Growth Differ. 6, 1235-1244 (1995).
64. Erwin, R. A., Kirken, R. A., Malabarba, M. G., Farrar, W. L. & Rui, H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology 136, 3512-3518 (1995).
65. Buckley, A. R., Rao, Y. P., Buckley, D. J. & Gout, P. W. Prolactin-induced phosphorylation and nuclear translocation of MAP kinase in Nb2 lymphoma cells. Biochem. Biophys. Res. Commun. 204, 1158-1164 (1994). (Pubitemid 24367173)
66. Clevenger, C. V. & Medaglia, M. V. The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. Mol. Endocrinol. 8, 674-681 (1994).
67. Berlanga, J. J., Vara, J. A. F., Martin-Perez, J. & Garcia-Ruiz, J. P. Prolactin receptor is associated with c-src kinase in rat liver. Mol. Endocrinol. 9, 1461-1467 (1995).
68. Too, C. K., Shiu, R. P. & Friesen, H. G. Cross-linking of G.-proteins to the prolactin receptor in rat NB2 lymphoma cells. Biochem. Biophys. Res. Commun. 173, 48-52 (1990).
69. Berlanga, J. J. et al. Prolactin activates tyrosyl phosphorylation of insulin receptor substrate 1 and phosphatidylinositol-3-OH kinase. J. Biol. Chem. 272, 2050-2052 (1997). (Pubitemid 27058477)
70. al-Sakkaf, K. A., Dobson, P. R. & Brown, B. L. Activation of phosphatidylinositol 3-kinase by prolactin in Nb2 cells. Biochem. Biophys. Res. Commun. 221, 779-784 (1996). (Pubitemid 26153940)
71. Clevenger, C. V., Furth, P. A., Hankinson, S. E. & Schuler, L. A. The role of prolactin in mammary carcinoma. Endocr. Rev. 24, 1-27 (2003). (Pubitemid 36223277)
72. Neilson, L. M. et al. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol. Endocrinol. 21, 2218-2232 (2007). (Pubitemid 47347383)
73. Levy, D. E. & Darnell, J. E. Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662 (2002). (Pubitemid 34987786)
74. Yu, H. & Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (2004). (Pubitemid 38198738)
75. Schindler, C., Levy, D. E. & Decker, T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 20059-20063 (2007). (Pubitemid 47099977)
76. Mui, A. et al. Function of the common beta subunit of the GM-CSF/IL-3/IL-5 receptors. Adv. Exp. Med. Biol. 365, 217-223 (1994). (Pubitemid 24353291)
77. Liu, X., Robinson, G. W., Gouilleux, F., Groner, B. & Hennighausen, L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl Acad. Sci. USA 92, 8831-8835 (1995).
78. Liu, J. X., Mietz, J., Modi, W. S., John, S. & Leonard, W. J. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J. Biol. Chem. 271, 10738-10744 (1996). (Pubitemid 26145810)
79. Reich, N. C. & Liu, L. Tracking STAT nuclear traffic. Nat. Rev. Immunol. 6, 602-612 (2006). (Pubitemid 44134093)
80. Vinkemeier, U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J. Cell Biol. 167, 197-201 (2004). (Pubitemid 39435062)
81. Sekimoto, T., Nakajima, K., Tachibana, T., Hirano, T. & Yoneda, Y. Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4. J. Biol. Chem. 271, 31017-31020 (1996). (Pubitemid 26408535)
82. Sekimoto, T., Imamoto, N., Nakajima, K., Hirano, T. & Yoneda, Y. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J. 16, 7067-7077 (1997). (Pubitemid 27520806)
83. Kawashima, T. et al. A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors. Mol. Cell Biol. 29, 1796-1813 (2009).
84. Marg, A. et al. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J. Cell Biol. 165, 823-833 (2004). (Pubitemid 38821973)
85. Soldaini, E. et al. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol. Cell Biol. 20, 389-401 (2000). (Pubitemid 30002580)
86. Dagvadorj, A., Kirken, R. A., Leiby, B., Karras, J. & Nevalainen, M. T. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin. Cancer Res. 14, 1317-1324 (2008). (Pubitemid 351413910)
87. Li, H. et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin. Cancer Res. 11, 5863-5868 (2005). (Pubitemid 41170314)
88. Kazansky, A. V., Spencer, D. M. & Greenberg, N. M. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res. 63, 8757-8762 (2003). (Pubitemid 38064054)
89. Gu, L. et al. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am. J. Pathol. 176, 1959-1972 (2010).
90. Gu, L. et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr. Relat. Cancer 17, 481-493 (2010).
91. Tan, S. H. et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res. 68, 236-248 (2008).
92. Isaacs, J. T. & Isaacs, W. B. Androgen receptor outwits prostate cancer drugs. Nat. Med. 10, 26-27 (2004). (Pubitemid 38524693)
93. Thomas, C. et al. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol. Cancer Ther. 10, 347-359.
94. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001). (Pubitemid 33741879)
95. Goffin, V., Bernichtein, S., Touraine, P. & Kelly, P. A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26, 400-422 (2005). (Pubitemid 40686651)
96. Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (2006). (Pubitemid 44213229)
97. Arrighi, N. et al. Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract. Neurourol. Urodyn. 28, 343-348 (2009).
98. Arvigo, M. et al. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J. Endocrinol. 207, 309-317 (2010).
99. Eyal, O., Jomain, J. B., Kessler, C., Goffin, V. & Handwerger, S. Autocrine prolactin inhibits human uterine decidualization: a novel role for prolactin. Biol. Reprod. 76, 777-783 (2007). (Pubitemid 46651218)
100. Howell, S. J., Anderson, E., Hunter, T., Farnie, G. & Clarke, R. B. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res. 10, R68 (2008).
101. Llovera, M. et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19, 4695-4705 (2000).
102. Tallet, E. et al. Rational design of competitive prolactin/growth hormone receptor antagonists. J. Mammary Gland Biol. Neoplasia 13, 105-117 (2008).
103. Wu, W., Ginsburg, E., Vonderhaar, B. K. & Walker, A. M. S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res. 65, 7509-7515 (2005). (Pubitemid 41161287)
104. Xu, J. et al. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol. Endocrinol. 25, 597-610 (2011).
105. Tefferi, A. & Gilliland, D. G. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin. Proc. 80, 947-958 (2005). (Pubitemid 40911470)
106. Levine, R. L. et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106, 3377-3379 (2005). (Pubitemid 41609169)
107. Frohling, S. et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 107, 1242-1243 (2006). (Pubitemid 43156337)
108. Gu, L. et al. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer. Anal. Cell Pathol. (Amst). 33, 55-59 (2010).
109. Ferrajoli, A. et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 67, 11291-11299 (2007). (Pubitemid 350248555)
110. Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
111. Guh, J. Y. et al. Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am. J. Kidney Dis. 38, 1096-1104 (2001).
112. Nagel-Wolfrum, K. et al. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res. 2, 170-182 (2004). (Pubitemid 39030307)
113. Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276, 45443-45455 (2001).
114. Turkson, J. et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3, 261-269 (2004). (Pubitemid 39193701)
115. Numata, A. et al. Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway. J. Biol. Chem. 280, 12621-12629 (2005).
116. Malin, S. et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat. Immunol. 11, 171-179 (2010).
117. Goffin, V. & Kelly, P. A. The prolactin/growth hormone receptor family: structure/function relationships. J. Mammary Gland Biol. Neoplasia 2, 7-17 (1997). (Pubitemid 127717408)
118. Hu, Z. Z., Meng, J. & Dufau, M. L. Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J. Biol. Chem. 276, 41086-41094 (2001).
119. Arden, K. C., Boutin, J. M., Djiane, J., Kelly, P. A. & Cavenee, W. K. The receptors for prolactin and growth hormone are localized in the same region of human chromosome 5. Cytogenet. Cell Genet. 53, 161-165 (1990). (Pubitemid 20189241)
120. Kelly, P. A. et al. The growth hormone/prolactin receptor family. Recent Prog. Horm. Res. 48, 123-164 (1993).
121. Boutin, J. M. et al. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell 53, 69-77 (1988).
122. Buteau, H. et al. N-glycosylation of the prolactin receptor is not required for activation of gene transcription but is crucial for its cell surface targeting. Mol. Endocrinol. 12, 544-55 (1998). (Pubitemid 30659085)
123. Rui, H., Kirken, R. A. & Farrar, W. L. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J. Biol. Chem. 269, 5364-5368 (1994). (Pubitemid 24239533)
124. Becker, S., Groner, B. & Muller, C. W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394, 145-151 (1998). (Pubitemid 28325960)
125. Chen, X. et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93, 827-839 (1998). (Pubitemid 28257588)
126. Decker, T. & Kovarik, P. Serine phosphorylation of STATs. Oncogene 19, 2628-2637 (2000). (Pubitemid 30339219)
127. Decker, T. & Kovarik, P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell. Mol. Life Sci. 55, 1535-1546 (1999). (Pubitemid 29445819)
128. Horvath, C. M., Wen, Z. & Darnell, J. E. Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9, 984-994 (1995).